RPL23AP37

Across TCGA pan-cancer cohorts, RPL23AP37 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RPL23AP37’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RPL23AP37 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL23AP37 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

LIHC, COAD, and KIRC are the cancer types where RPL23AP37 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL23AP37 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.090	<.001	7	view →
COAD	All	All	+0.254	.001	4	view →
KIRC	All	All	+0.082	.013	3	view →
CHOL	All	All	+0.157	.009	2	view →
LUSC	All	II,III,IV	+0.169	.034	1	view →
LUAD	All	All	+0.163	.029	1	view →
KICH	Female	All	−0.131	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RPL23AP37–LIHC

Open the LIHC breakdown →